ENDRA Life Sciences Inc. Quarterly Operating Income (Loss) in USD from Q1 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
ENDRA Life Sciences Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2016 to Q3 2024.
  • ENDRA Life Sciences Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$1.51M, a 51.8% increase year-over-year.
  • ENDRA Life Sciences Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$7.98M, a 35.5% increase year-over-year.
  • ENDRA Life Sciences Inc. annual Operating Income (Loss) for 2023 was -$10.5M, a 20% increase from 2022.
  • ENDRA Life Sciences Inc. annual Operating Income (Loss) for 2022 was -$13.2M, a 14.4% decline from 2021.
  • ENDRA Life Sciences Inc. annual Operating Income (Loss) for 2021 was -$11.5M, a 0.03% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$7.98M -$1.51M +$1.62M +51.8% Jul 1, 2024 Sep 30, 2024 10-Q/A 2024-11-21
Q2 2024 -$9.6M -$2.23M +$764K +25.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$10.4M -$2.78M +$159K +5.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$10.5M -$1.46M +$1.86M +56% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$12.4M -$3.13M +$288K +8.43% Jul 1, 2023 Sep 30, 2023 10-Q/A 2024-11-21
Q2 2023 -$12.7M -$2.99M +$577K +16.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$13.2M -$2.94M -$84.1K -2.94% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$13.2M -$3.31M -$242K -7.87% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$12.9M -$3.42M -$766K -28.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$12.1M -$3.57M -$372K -11.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$11.8M -$2.86M -$279K -10.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$11.5M -$3.07M -$817K -36.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 -$10.7M -$2.65M +$605K +18.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$11.3M -$3.2M -$309K -10.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$11M -$2.58M +$525K +16.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$11.5M -$2.25M +$876K +28% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-30
Q3 2020 -$12.4M -$3.26M -$615K -23.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$11.8M -$2.89M -$566K -24.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$11.2M -$3.1M -$354K -12.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 -$10.8M -$3.13M -$1.13M -56.3% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 -$9.72M -$2.64M -$285K -12.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$9.43M -$2.33M -$502K -27.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 -$8.93M -$2.75M +$90.4K +3.19% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 -$9.02M -$2M +$295K +12.8% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-26
Q3 2018 -$9.31M -$2.36M -$1.44M -159% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 -$7.87M -$1.82M -$766K -72.5% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 -$7.1M -$2.84M -$2.48M -687% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
Q4 2017 -$4.63M -$2.3M -$1.98M -621% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-11
Q3 2017 -$2.65M -$911K -$306K -50.5% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-05
Q2 2017 -$2.34M -$1.06M -$563K -114% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2017 -$1.78M -$361K +$12.8K +3.42% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-15
Q4 2016 -$1.79M -$319K Oct 1, 2016 Dec 31, 2016 10-K 2018-03-20
Q3 2016 -$605K Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-14
Q2 2016 -$494K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-07
Q1 2016 -$373K Jan 1, 2016 Mar 31, 2016 10-Q 2017-06-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.